Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ACCENDRA HEALTH INC/VA/OMI · Entity 6858 | EVP, Chief Financial Officer | February 08, 2018 | February 12, 2018 |
| ACCURAY INCARAY · Entity 1170 | Director | October 05, 2026 | October 07, 2026 |
| BIOMARIN PHARMACEUTICAL INCBMRN · Entity 2404 | Director | December 31, 2025 | February 14, 2026 |
| Intersect ENT, Inc.XENT · Entity 127294 | EVP & Chief Financial Officer | May 13, 2022 | May 16, 2022 |
| Rockley Photonics Holdings LtdRKLY · Entity 122956 | President & CFO | October 21, 2022 | October 21, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ACCENDRA HEALTH INC/VA/
Report date February 08, 2018 · Filed February 12, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 127,158 |
Reported balance
After 2018-02-08 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2018-02-08 · Grant · Acquired 22,013 · Balance 127,158 F1: Restricted stock with three year vesting date. F2: Balance includes employee stock purchase plan holdings and/or shares acquired through dividend reinvestment transactions not previously reflected in beneficial ownership total. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock with three year vesting date.
F2: Balance includes employee stock purchase plan holdings and/or shares acquired through dividend reinvestment transactions not previously reflected in beneficial ownership total.
ACCURAY INC
Report date October 05, 2026 · Filed October 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 75,000 |
Reported balance
After 2026-10-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-10-05 · Grant · Acquired 75,000 · Balance 75,000 F1: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F2: This represents a Restricted Stock Unit that vests in three equal annual installments beginning on the first anniversary of the grant date. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.30 · Expires 2033-10-05 | Direct | 75,000 |
Reported balance
After 2026-10-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-10-05 · Grant · Acquired 75,000 · Balance 75,000 F3: This represents a Non-Qualified Stock Option that will vest in three equal annual installments beginning on the first anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each RSU represents a contingent right to receive one share of the Issuer's common stock.
F2: This represents a Restricted Stock Unit that vests in three equal annual installments beginning on the first anniversary of the grant date.
F3: This represents a Non-Qualified Stock Option that will vest in three equal annual installments beginning on the first anniversary of the grant date.
BIOMARIN PHARMACEUTICAL INC
Report date December 31, 2025 · Filed February 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 126,926 |
Reported balance
After 2025-12-30 transaction · row 1
1 source rowRow 1 · 2025-12-30 · Gift · Disposed 500 · Balance 126,926 |
Intersect ENT, Inc.
Report date May 13, 2022 · Filed May 16, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2022-05-13 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2022-05-13 · Other · Disposed 57,230 · Balance 106,366 F1: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit that was subject to performance-based vesting conditions (each, an 'Issuer PSU') that was outstanding and became vested prior to or upon the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer PSU and (2) the Common Stock Merger Consideration, subject to any required withholding of taxes. Row 2 · 2022-05-13 · Other · Disposed 65,759 · Balance 40,607 F2: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit that was subject to vesting conditions based solely on continued employment with or service to the Company or any of its subsidiaries (each, an 'Issuer RSU') that was outstanding and unvested immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer RSU and (2) the Common Stock Merger Consideration, subject to any required withholding of taxes. Row 3 · 2022-05-13 · Other · Disposed 40,607 · Balance 0 F3: Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger (the 'Merger Agreement'), dated August 6, 2021, by and among the Issuer, Medtronic, Inc. ('Parent') and Project Kraken Merger Sub, Inc., a wholly-owned subsidiary of Parent ('Merger Sub'), including the consummation of the merger (the 'Merger') between Issuer and Merger Sub on May 13, 2022. Pursuant to the Merger Agreement, as of the effective time of the Merger (the 'Effective Time'), [each outstanding share of Issuer common stock, $0.001 par value per share ('Issuer Common Stock'), was cancelled, retired and converted into the right to receive an amount equal to $28.25 in cash, without interest thereon (the 'Common Stock Merger Consideration'), subject to any required withholding of taxes]. F4: Includes 4,400 shares at the children's trust. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.07 · Expires 2031-02-01 | Direct | 0 |
Reported balance
After 2022-05-13 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-05-13 · Other · Disposed 34,000 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.60 · Expires 2029-11-26 | Direct | 0 |
Reported balance
After 2022-05-13 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-05-13 · Other · Disposed 74,852 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit that was subject to performance-based vesting conditions (each, an 'Issuer PSU') that was outstanding and became vested prior to or upon the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer PSU and (2) the Common Stock Merger Consideration, subject to any required withholding of taxes.
F2: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit that was subject to vesting conditions based solely on continued employment with or service to the Company or any of its subsidiaries (each, an 'Issuer RSU') that was outstanding and unvested immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer RSU and (2) the Common Stock Merger Consideration, subject to any required withholding of taxes.
F3: Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger (the 'Merger Agreement'), dated August 6, 2021, by and among the Issuer, Medtronic, Inc. ('Parent') and Project Kraken Merger Sub, Inc., a wholly-owned subsidiary of Parent ('Merger Sub'), including the consummation of the merger (the 'Merger') between Issuer and Merger Sub on May 13, 2022. Pursuant to the Merger Agreement, as of the effective time of the Merger (the 'Effective Time'), [each outstanding share of Issuer common stock, $0.001 par value per share ('Issuer Common Stock'), was cancelled, retired and converted into the right to receive an amount equal to $28.25 in cash, without interest thereon (the 'Common Stock Merger Consideration'), subject to any required withholding of taxes].
F4: Includes 4,400 shares at the children's trust.
F5: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes.
Rockley Photonics Holdings Ltd
Report date October 21, 2022 · Filed October 21, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 1,891,521 |
Reported balance
After 2022-10-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-10-21 · Grant · Acquired 1,891,521 · Balance 1,891,521 F1: The RSU will vest over 4 years, with 25% vesting on the first anniversary of the date of grant, and the remaining 75% vesting in quarterly installments over the remaining 3 years, subject to continued service and acceleration upon a change in control. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.63 | Direct | 1,891,521 |
Reported balance
After 2022-10-21 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-10-21 · Grant · Acquired 1,891,521 · Balance 1,891,521 F2: The Stock Option will vest over 4 years, with 25% vesting on the first anniversary of the date of grant, and the remaining 75% vesting in quarterly installments over the remaining 3 years, subject to continued service and acceleration upon a change in control. |
Filing footnotes · ownership attribution and instrument terms
F1: The RSU will vest over 4 years, with 25% vesting on the first anniversary of the date of grant, and the remaining 75% vesting in quarterly installments over the remaining 3 years, subject to continued service and acceleration upon a change in control.
F2: The Stock Option will vest over 4 years, with 25% vesting on the first anniversary of the date of grant, and the remaining 75% vesting in quarterly installments over the remaining 3 years, subject to continued service and acceleration upon a change in control.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 13, 2018 Filed Sep 17, 2018 23:22 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 3,000 | $21.51 | $64,530.00 |
DisclosureSEC source: 0001567619-18-002765 · doc1.xml · nonDerivative · entry 2 MEIER RICHARD A · CIK 0001227305 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,610 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 13, 2018 Filed Sep 17, 2018 23:22 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 12,000 | $21.51 | $258,120.00 |
DisclosureSEC source: 0001567619-18-002765 · doc1.xml · nonDerivative · entry 1 MEIER RICHARD A · CIK 0001227305 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,610 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 27, 2018 Filed Aug 29, 2018 19:51 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 13,000 | $0.00 Strike: $14.39 | $0.00 |
DisclosureSEC source: 0001567619-18-001878 · doc1.xml · derivative · entry 5 MEIER RICHARD A · CIK 0001227305 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,000 shares Expires 2019-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| August 27, 2018 Filed Aug 29, 2018 19:51 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 2,000 | $0.00 Strike: $14.39 | $0.00 |
DisclosureSEC source: 0001567619-18-001878 · doc1.xml · derivative · entry 4 MEIER RICHARD A · CIK 0001227305 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Stock · 2,000 shares Expires 2019-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| August 27, 2018 Filed Aug 29, 2018 19:51 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 2,000 | $100.12 | $200,235.40 |
DisclosureSEC source: 0001567619-18-001878 · doc1.xml · nonDerivative · entry 3 MEIER RICHARD A · CIK 0001227305 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,610 F1 · price: The price in column 4 is the weighted average price. The price actually received ranged from $100.112 to $100.130. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. Read SEC document |
| August 27, 2018 Filed Aug 29, 2018 19:51 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 2,000 | $14.39 | $28,780.00 |
DisclosureSEC source: 0001567619-18-001878 · doc1.xml · nonDerivative · entry 2 MEIER RICHARD A · CIK 0001227305 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,610 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 27, 2018 Filed Aug 29, 2018 19:51 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 13,000 | $14.39 | $187,070.00 |
DisclosureSEC source: 0001567619-18-001878 · doc1.xml · nonDerivative · entry 1 MEIER RICHARD A · CIK 0001227305 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,610 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 05, 2018 Filed Jun 8, 2018 00:55 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 4,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-027795 · doc1.xml · nonDerivative · entry 1 MEIER RICHARD A · CIK 0001227305 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,610 F1 · price: Restricted stock units granted on June 5, 2018. Price not applicable. F2 · balance_after: Amount of securities beneficially owned has been updated from the reporting person's prior report to include 1,000 shares inadvertently omitted from prior reports based on a reconciliation with the Company's records. Read SEC document |
| May 17, 2018 Filed May 18, 2018 22:33 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy) Common Stock · Derivative | 15,000 | $0.00 Strike: $38.59 | $0.00 |
DisclosureSEC source: 0001140361-18-024760 · doc1.xml · derivative · entry 2 MEIER RICHARD A · CIK 0001227305 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2018-05-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| May 17, 2018 Filed May 18, 2018 22:33 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 15,000 | $38.59 | $578,850.00 |
DisclosureSEC source: 0001140361-18-024760 · doc1.xml · nonDerivative · entry 1 MEIER RICHARD A · CIK 0001227305 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,310 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 08, 2018 Filed Feb 12, 2018 21:22 UTC | ACCENDRA HEALTH INC/VA/ OMI · Entity 6858 | GrantCommon Stock | 22,013 | $0.00 | $0.00 |
DisclosureSEC source: 0000075252-18-000030 · edgar.xml · nonDerivative · entry 1 MEIER RICHARD A · CIK 0001227305 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,158 F1 · security: Restricted stock with three year vesting date. F2 · balance_after: Balance includes employee stock purchase plan holdings and/or shares acquired through dividend reinvestment transactions not previously reflected in beneficial ownership total. Read SEC document |
| June 06, 2017 Filed Jun 8, 2017 22:21 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantStock Option (Right to buy) Common Stock · Derivative | 4,910 | $0.00 Strike: $89.60 | $0.00 |
DisclosureSEC source: 0001140361-17-024502 · doc1.xml · derivative · entry 2 MEIER RICHARD A · CIK 0001227305 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,910 Underlying: Common Stock · 4,910 shares Expires 2027-06-05 F2 · derivative.exercise_date: Option grant vests in full on June 6, 2018. Read SEC document |
| June 06, 2017 Filed Jun 8, 2017 22:21 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 2,050 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-024502 · doc1.xml · nonDerivative · entry 1 MEIER RICHARD A · CIK 0001227305 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,310 F1 · price: Restricted stock units granted on June 6, 2017. Price not applicable. Read SEC document |
| June 01, 2017 Filed Jun 2, 2017 15:02 UTC | ACCENDRA HEALTH INC/VA/ OMI · Entity 6858 | Tax withholdingCommon Stock | 4,941 | $31.88 | $157,519.08 |
DisclosureSEC source: 0000075252-17-000092 · edgar.xml · nonDerivative · entry 1 MEIER RICHARD A · CIK 0001227305 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,880 F1 · shares: Represents shares surrendered to the Issuer to satisfy tax withholding obligations in connection with vesting of restricted stock granted to Reporting Person. Read SEC document |
| May 05, 2017 Filed May 9, 2017 17:24 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 7,500 | $0.00 Strike: $17.33 | $0.00 |
DisclosureSEC source: 0001140361-17-019046 · doc1.xml · derivative · entry 2 MEIER RICHARD A · CIK 0001227305 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires 2017-06-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Reflects the number of stock options outstanding after the transaction from this specific stock option grant. Read SEC document |
| May 05, 2017 Filed May 9, 2017 17:24 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 7,500 | $17.33 | $129,975.00 |
DisclosureSEC source: 0001140361-17-019046 · doc1.xml · nonDerivative · entry 1 MEIER RICHARD A · CIK 0001227305 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,260 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 09, 2017 Filed Feb 13, 2017 17:51 UTC | ACCENDRA HEALTH INC/VA/ OMI · Entity 6858 | GrantCommon Stock | 11,455 | $0.00 | $0.00 |
DisclosureSEC source: 0000075252-17-000024 · edgar.xml · nonDerivative · entry 2 MEIER RICHARD A · CIK 0001227305 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,821 F2 · security: Restricted stock vesting on 2/5/2018 F3 · balance_after: Balance includes employee stock purchase plan holdings and/or shares acquired through dividend reinvestment transactions not previously reflected in beneficial ownership total. Read SEC document |
| February 09, 2017 Filed Feb 13, 2017 17:51 UTC | ACCENDRA HEALTH INC/VA/ OMI · Entity 6858 | GrantCommon Stock | 9,747 | $0.00 | $0.00 |
DisclosureSEC source: 0000075252-17-000024 · edgar.xml · nonDerivative · entry 1 MEIER RICHARD A · CIK 0001227305 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,103 F1 · security: Restricted stock with three year vesting date. Read SEC document |
| February 06, 2017 Filed Feb 7, 2017 19:19 UTC | ACCENDRA HEALTH INC/VA/ OMI · Entity 6858 | Tax withholdingCommon Stock | 3,823 | $36.00 | $137,628.00 |
DisclosureSEC source: 0000075252-17-000014 · edgar.xml · nonDerivative · entry 1 MEIER RICHARD A · CIK 0001227305 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,297 F1 · shares: Represents shares surrendered to the Issuer to satisfy tax withholding obligations in connection with vesting of restricted stock granted to Reporting Person. Read SEC document |
| February 06, 2017 Filed Feb 13, 2017 17:43 UTC Amendment | ACCENDRA HEALTH INC/VA/ OMI · Entity 6858 | Tax withholdingCommon Stock | 3,823 | $36.00 | $137,628.00 |
DisclosureSEC source: 0000075252-17-000023 · edgar.xml · nonDerivative · entry 1 MEIER RICHARD A · CIK 0001227305 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,356 F1 · shares: Represents shares surrendered to the Issuer to satisfy tax withholding obligations in connection with vesting of restricted stock granted to Reporting Person. F2 · balance_after: Correction to beneficial ownership due to administrative error. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.